Highlights
- Esperion announces results from Phase 1 study and four preclinical studies for ETC-1002
May 2, 2011 - Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
January 6, 2011 - TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
June 21, 2010
